ED50 variation of propofol when co-administered with nalbuphine for intravenous anesthesia in hysteroscopic examination and treatment surgery: a randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042342

Enrollment

Unknown

Registered

2021-01-19

Start date

2021-01-18

Completion date

Unknown

Last updated

2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intravenous anesthesia in hysteroscopic examination or operation

Interventions

A:Nalbuphine 0.1mg/kg

B:Nalbuphine 0.2mg/kg

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective hysteroscopy, grade ASA I-II; 2. Aged 18-60 years; 3. BMI 18-25 kg/m2; 4. Normal communication; 5. Voluntary subjects and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe respiratory and circulatory diseases, such as severe coronary heart disease and COPD; 2. Diseases of the endocrine system, such as pituitary tumor, severe diabetes, hypercortisolism, pheochromocytoma; 3. Mental and psychological diseases, such as schizophrenia, depression, history of chronic analgesic drug use, history of alcohol abuse, opioid dependence; 4. History of allergy to anesthetic drugs.

Design outcomes

Secondary

Measure	Time frame
Respiratory depression;Duration time given initial dose of propofol;Duration of procedure;	—

Primary

Measure	Time frame
dosage of Propofol;dosage of Nalbuphine;Recovery time;Median effective dose;	—

Countries

China

Contacts

Public ContactChen Chen

The First Affiliated Hospital of Anhui Medical University

cc3014@126.com+86 15922410728

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026